TY - JOUR
AU1 - Clearwater, Whitney
AU2 - Kassam, Farzaan
AU3 - Aalami Harandi, Arshia
AU4 - Tenggardjaja, Christopher F.
AU5 - Abraham, Nitya
AB - Purpose of ReviewTo evaluate recent literature on combination and novel pharmacologic therapies for overactive bladder (OAB).Recent FindingsCombination therapies demonstrating greater efficacy than monotherapy include combination anticholinergics, anticholinergic plus β-3 agonist, and anticholinergic with behavioral modification, percutaneous tibial nerve stimulation, or sacral neuromodulation. Promising novel therapies include new bladder selective anticholinergics, new β-3 agonists, and gabapentin.SummaryOAB is a symptom complex caused by dysfunction in the interconnected neural, muscular, and urothelial systems that control micturition. Although several therapeutic targets and treatment options exist, complete resolution is not always achieved, discontinuation rate for medical therapy is high, and few patients subsequently progress to third-line treatment options. Recent literature suggests combination therapy diversifying therapeutic targets is more effective than targeting a single pathway and novel treatments targeting additional pathways have promising results.
TI - Combination and Novel Pharmacologic Agents for OAB
JF - Current Urology Reports
DO - 10.1007/s11934-022-01097-7
DA - 2022-07-01
UR - https://www.deepdyve.com/lp/springer-journals/combination-and-novel-pharmacologic-agents-for-oab-sMTx2Ma2BV
SP - 129
EP - 141
VL - 23
IS - 7
DP - DeepDyve
ER -